Answers are grounded in this paper and cite their sources.
Homologous recombination deficiency (HRD), caused by impaired homologous recombination repair (HRR), represents a clinically relevant molecular phenotype associated with genomic instability and therapeutic vulnerability. However, current HRD assessment relies mainly on tissue-based molecular assays, limiting its application in routine clinical practice. This study aimed to develop and validate a computed tomography (CT)-based deep radiomics signature (DRS) for noninvasive prediction of HRD status and to investigate its prognostic value and its association with outcomes after adjuvant chemotherapy in colorectal cancer (CRC). This multicenter retrospective study included 2065 patients with CRC from three hospitals in China. Among the 210 patients used for model training, 73 were classified as HRD and 137 as homologous recombination proficient (HRP). Radiomic and deep learning features were extracted from preoperative CT images. After feature selection, seven machine learning models were developed and compared. The optimal model was used to establish the DRS, which was further evaluated for HRD prediction and survival stratification in independent cohorts. Exploratory observational analyses examined whether associations between adjuvant chemotherapy and survival differed by DRS classification. Transcriptomic analysis was performed to explore the biological characteristics associated with the DRS-defined HRD phenotype. The DRS model demonstrated favorable discrimination for HRD status in the training, internal validation, and external validation cohorts, with AUCs of 0.873, 0.858, and 0.826, respectively. DRS classification effectively stratified overall survival (OS) and disease-free survival (DFS) across all cohorts. Multivariable Cox regression analysis showed that DRS remained independently associated with prognosis in CRC patients (all P < 0.001). Among patients with stage IIB-III CRC, adjuvant chemotherapy was associated with improved survival in the DRS-HRD subgroup, whereas no similar association was observed in the DRS-HRP subgroup. Transcriptomic analysis further showed that genes upregulated in DRS-HRD tumors were enriched in pathways related to cell cycle, DNA replication, and homologous recombination. The CT-based DRS noninvasively predicted the study-specific reference HRD label and stratified prognosis. In exploratory observational analyses, associations between adjuvant chemotherapy and survival differed by DRS group among patients with stage IIB-III disease.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: